HC Wainwright Reaffirms “Buy” Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 313.22% from the stock’s previous close. HC Wainwright also issued estimates for Pyxis Oncology’s Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS and FY2029 earnings at $0.18 EPS.

Separately, Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Pyxis Oncology Trading Down 1.6%

Shares of PYXS opened at $1.21 on Monday. The stock has a 50 day simple moving average of $1.06 and a 200-day simple moving average of $1.60. The stock has a market cap of $74.96 million, a PE ratio of -1.17 and a beta of 1.15. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, sell-side analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC increased its stake in shares of Pyxis Oncology by 53.8% in the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after buying an additional 1,043,228 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock worth $939,000 after acquiring an additional 219,100 shares during the last quarter. 683 Capital Management LLC increased its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after acquiring an additional 135,000 shares in the last quarter. Pier 88 Investment Partners LLC raised its stake in shares of Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock worth $383,000 after acquiring an additional 292,370 shares during the last quarter. Finally, Ridgeback Capital Investments L.P. bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $560,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.